Merck Seeks Oxytrol Switch For Women As First Overactive Bladder OTC
This article was originally published in The Tan Sheet
Executive Summary
Merck will present to FDA’s Nonprescription Drugs Advisory Committee Nov. 9 in support of switching Watson’s Oxytrol as a female-specific OTC.
You may also be interested in...
Merck’s Oxytrol Could Go From Rx Also-Ran To OTC Star – Analysts
Watson’s Oxytrol currently has just a 1% share of the overactive bladder drug market, but Kline and Kalorama analysts see sizable potential should it switch OTC.
Merck’s Oxytrol Could Go From Rx Also-Ran To OTC Star – Analysts
Watson’s Oxytrol currently has just a 1% share of the overactive bladder drug market, but Kline and Kalorama analysts see sizable potential should it switch OTC.
Merck’s Oxytrol Could Go From Rx Also-Ran To OTC Star – Analysts
Watson’s Oxytrol currently has just a 1% share of the overactive bladder drug market, but Kline and Kalorama analysts see sizable potential should it switch OTC.